Clinical Trial Update: Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tiotropium (2.5 and 5 mcg once daily via Respimat) versus placebo and salmeterol HFA MDI in adults with moderate persistent asthma; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Serevent (salmeterol)
• Spiriva (tiotropium) (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2014-02-07